Search results
Results from the WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK would share additional data with U.S. agencies by the end of this year, she said. Citing the U.S. agency's decision, GSK cut its forecast for 2024 vaccine sales. It now expects that business ...
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.
(Reuters) -GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British drugmaker's annual report ...
By Yadarisa Shabong and Maggie Fick. (Reuters) -GSK shares fell as much as 7% on Thursday, a day after a U.S. public health agency narrowed its age recommendation for use of respiratory syncytial ...
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4][5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [8][9]
GSK on Wednesday raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine.